WHO recommends now not utilizing two antibody remedies towards Covid-19 – rts.ch

Within the newest model of their information to anti-Covid remedies, printed in a single day from Thursday to Friday within the British Medical Journal, WHO specialists “strongly advocate” to not use Xevudy (primarily based on the molecule sotrovimab) and Ronapreve (casirivimab-imdevimab mixture).

These two remedies with artificial antibodies towards Covid have thus far been really useful with warning by the WHO for sufferers with a gentle type of the illness with a threat of development to a extra critical kind.

>> Learn: Switzerland buys medicines for the prevention of Covid-19

New round remdesivir

However the arrival of the Omicron variant on the finish of 2021 referred to as into query the curiosity of those remedies and WHO specialists, on the idea of a number of in vitro research, now consider that they’re in all probability ineffective towards the strains in circulation.

The specialists have, on the identical time, up to date suggestions on different remedies, particularly remdesivir from the Gilead laboratory. This therapy, which the WHO had beforehand solely really useful to be used within the case of a gentle type of Covid, can, within the mild of latest research, be thought-about in sure critical circumstances, in line with specialists.

Nevertheless, in essentially the most critical circumstances, referred to as “vital”, the research don’t present a good thing about remdesivir. Consultants subsequently advise towards its use in these circumstances. Even in circumstances the place it may be used, this therapy has solely a “modest” curiosity with a level of certainty which is just “average”, nevertheless warn the specialists.

>> Learn additionally: Strategies used for individuals in respiratory misery attributable to Covid-19

Remedy approved and reimbursed in Switzerland

On the identical time, the corporate AstraZeneca introduced on Thursday {that a} therapy towards Covid-19 had obtained emergency authorization from Swissmedic, and can be reimbursed by the Confederation or medical health insurance underneath sure situations. In keeping with AstraZeneca, the Confederation has already ordered 5,000 doses.

>> Examine it: Monoclonal antibodies towards Covid for individuals in danger

In a press launch, the pharmaceutical laboratory specifies that this primary drug prophylaxis reimbursed in Switzerland is a mixture of tixagevimab and cilgavimab antibodies (AZD7442). It’s meant for sufferers in danger who, regardless of a number of vaccinations, haven’t been in a position to generate adequate immune defenses towards Covid-19. Both immunocompromised individuals affected by most cancers, rheumatoid arthritis or transplant recipients.

Switzerland has roughly 200,000 immunocompromised sufferers. Consultants estimate that there are round 10,000 high-risk sufferers within the nation.

Swissmedic has approved the therapy on an accelerated foundation and for a restricted interval. It may be administered to adults and younger individuals from the age of 12. Different purposes for approval, particularly for therapy after publicity to Covid, are being examined. The product is run as an intramuscular injection.

ats/jop